Engineered immune cells show promise against tough lymphoma
NCT ID NCT04880434
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tested a personalized cell therapy called KTE-X19 (brexucabtagene autoleucel) in 95 adults with mantle cell lymphoma that had returned or stopped responding to prior treatments. Participants received a single infusion of their own genetically modified immune cells designed to attack the cancer. The main goal was to see how many patients had their tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Brexucabtagene autoleucel (KTE-X19), a CAR T-cell therapy made from the patient's own immune cells
- What this could lead to
- If successful, this could provide a powerful treatment option for people with mantle cell lymphoma that has stopped responding to other therapies.
- What could go wrong
- This is a phase 2 trial with 95 participants, so results are not yet confirmed in larger groups. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and neurological problems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Academisch Medisch Centrum
Amsterdam, 1100, Netherlands
-
Advocate Aurora Health - Advocate Lutheran General Hospital
Park Ridge, Illinois, 60068, United States
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
Baylor Cancer Hospital
Dallas, Texas, 75246, United States
-
CHU de Montpellier
Montpellier, 34295, France
-
CHU de Rennes
Rennes, 35033, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Cleveland Clinic - Taussig Cancer Institute
Cleveland, Ohio, 44195, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University
Durham, North Carolina, 27710, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Erasmus MC
Rotterdam, 3015 CE, Netherlands
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Hopital Haut-Leveque
Pessac, 44035, France
-
Hospital Clinic Barcelona
Barcelona, Spain
-
Hospital Saint Louis
Paris, 75010, France
-
Hospital Universitari Vall D'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario de Salamanca
Salamanca, 37007, Spain
-
Johannes Gutenberg University Hospital-University Mainz
Mainz, 55101, Germany
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Kings College Hospital
London, SE5 9RS, United Kingdom
-
Loyola University Medical Center
Maywood, Illinois, 60153, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Manchester Royal Infirmary
Manchester, M13 9WL, United Kingdom
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Munich University of Technology-Medical Faculty- Ethics Committee
München, 81377, Germany
-
Ohio State University
Columbus, Ohio, 43220, United States
-
Queen Elizabeth University Hospital
Glasgow, G51 4TF, United Kingdom
-
Sarah Cannon - Tenessee
Nashville, Tennessee, 37203, United States
-
Sarah Cannon- Denver
Denver, Colorado, 80218, United States
-
Stanford University
Palo Alto, California, 94305, United States
-
Swedish Cancer Institute
Seattle, Washington, 98104, United States
-
Universitaetsklinikum Wuerzburg
Würzburg, 97080, Germany
-
University California Los Angeles (UCLA)
Santa Monica, California, 90404, United States
-
University Medical Center Groningen
Groningen, 9700 RB, Netherlands
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Miami
Miami, Florida, 33136, United States
-
University of Rochester
Rochester, New York, 14642, United States
-
Vanderbilt University
Nashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cancer biopsy predict who responds to a new immunotherapy?
- New drug combo shows promise for Tough-to-Treat lymphoma
- New hope for tough lymphoma: experimental drug shows promise
- Engineered immune cells show promise against tough lymphoma
- Experimental CAR-T therapy takes on relapsed blood cancers
- CAR T-Cell therapy takes on tough blood cancers in japanese trial